MedTrace Logo

Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children

NCT00682344 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2014-08-28

No results posted yet for this study

Summary

Levobupivacaïne (Chirocaine®) is a new local anaesthetic recently marketed in France. The goal of this prospective work is to study the pharmacokinetic aspect of this drug after injection around the sciatic nerve (subgluteal way).

Conditions

  • Surgical Pathology of the Leg or the Foot.

Interventions

DRUG

Levobupivacaïne

1,75mg/kg

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Frédéric LACROIX, MD · ASSISTANCE PUBLIQUE DES HOPITAUX DE MARSEILLE

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00682344 on ClinicalTrials.gov